Advertisement

Volume 130, Issue 15

Cover Figure: Twinfilin regulates platelet reactivity in a unique way for cytoskeleton-related protein. See the article by Stritt et al.

WASHINGTON, October 12, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia
RUNX1 is one of the best-characterized hematopoietic transcription factors. The investigators demonstrate an oncogenic role for RUNX1 in T-cell acute lymphoblastic leukemia (T-ALL) which contrasts with the tumor suppressor role of RUNX1 previously identified in T-ALL and myelodysplastic syndrome.

Twinfilin 2a regulates platelet reactivity and turnover in mice
This paper describes how twinfilin 2a, an actin-binding protein, negatively regulates platelet reactivity and turnover in a manner that is different from other cytoskeleton-related proteins.

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
Rosendaal and colleagues provide important new data on the interplay between genetics and treatment that impacts inhibitor formation in hemophilia A.

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
This paper reports on a large cohort of patients presenting with major bleeding on rivaroxaban or apixaban in whom the efficacy and safety of reversal of anticoagulation with prothrombin complex concentrate has been evaluated.

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
The authors describe the clinical efficacy of the histone deacetylase inhibitor vorinostat in the prevention of severe acute graft-versus-host disease in a high-risk setting of myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation.

Racial and ethnic disparities in hematologic malignancies
In this Review, Kirtane and Lee shed light on the impact of racial and ethnic disparities on treatment outcome in patients with hematologic malignancies.

Inflammation: a key regulator of hematopoietic stem cell fate in health and disease
This Spotlight Review examines the role of inflammation in in hematopoietic stem cell maintenance in steady state and disease.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.